Regulatory approval

Published by the Health Service Executive. Approved

Pertuzumab/ trastuzumab (Phesgo) for the maintenance treatment of adult patients with HER2- positive metastatic or locally recurrent unresectable breast cancer, where this is a continuation of treatment for patients who have completed the chemotherapy component of the treatment.

This is written in the approval document.

Reimbursement

ODMS

Citation

Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6659/785_v3_Pertuzumab_trastuzumab_Phesgo.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Pertuzumab, Trastuzumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-12-20	Health Service Executive	Indication approved for reimbursement.